CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that the first patient has been dosed in a Phase I clinical trial of CRS-100, the company’s lead immunotherapy product. The primary objectives of the study are to determine the maximum tolerated dose and to explore the safety profile of a single dose of CRS-100 in adult patients with cancer that has metastasized to the liver.
